Drug profile · INN
mirvetuximab soravtansine-gynx
ELAHERE
mirvetuximab soravtansine-gynx (ELAHERE) is a folate receptor alpha binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — mirvetuximab soravtansine-gynx
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
mirvetuximab soravtansine-gynx (ELAHERE) is a folate receptor alpha binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Folate receptor alpha binding agent
Primary target: Folate receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
AbbVie Secures FDA Approval for ImmunoGen's Elahere
Structured plan for AbbVie Secures FDA Approval for ImmunoGen's Elahere
FDA Approval Mirvetuximab Soravtansine: Accelerated OK for Elahere in Ovarian Cancer
The FDA has granted accelerated approval for Mirvetuximab Soravtansine, branded as Elahere, offering new hope for patients with ovarian cancer.
Related & competitor drugs
Frequently asked questions
What is mirvetuximab soravtansine-gynx?
mirvetuximab soravtansine-gynx (ELAHERE) is a folate receptor alpha binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for mirvetuximab soravtansine-gynx?
ELAHERE is a marketed brand name for mirvetuximab soravtansine-gynx. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mirvetuximab soravtansine-gynx?
mirvetuximab soravtansine-gynx has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.